Company news
Scienture Holdings, Inc. news in 2026
Scienture Holdings, Inc.'s news releases, calls and decks from 2026, newest first.
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
October 22, 2026
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
October 13, 2026
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
October 2, 2026
Scienture Holdings, Inc. Announces Reverse Stock Split
September 30, 2026
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
September 22, 2026
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
September 9, 2026
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
August 12, 2026
Securonix Takes on Data Costs, Detection Gaps, and AI Agent Risk at Black Hat USA 2026
August 3, 2026
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
July 9, 2026
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
June 18, 2026
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
June 8, 2026
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
June 3, 2026
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
June 2, 2026
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
May 18, 2026
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
May 7, 2026
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
May 6, 2026
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
April 14, 2026
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
April 5, 2026
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
March 29, 2026
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
March 10, 2026
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
February 3, 2026
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
January 14, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 17 slides · Sep 14, 2026
- Investor Presentation (May 2026)
Investor deck · 17 slides · May 5, 2026